Head, Engineered Small Molecules
Masahiko Hayakawa, Ph.D.
Masahiko Hayakawa has led research activities in the field of oncology and urology, creating multiple clinical and launched products. He assumed the Executive Director role in Modality Management in 2018, and the Head of Targeted Protein Degradation in 2019. He has been in his present position since April 2024.
Message from Masahiko
“Our goal is to deliver new therapeutic options to patients suffering from refractory diseases that have been difficult to treat with conventional drug therapies. We are committed to helping these patients with unmet medical needs.”
Head, Engineered Small Molecules-US/UK*
David Barrett, Ph.D.
*: subsidiaries of ESM